This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neoplasms  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Currently, peginterferon alfa-2b plus ribavirin has been shown to be the best available therapy for patients with chronic hepatitis C virus (HCV) infection.¹ Peginterferon alfa-2b (a 12-kDa linear polyethylene glycol moiety) plus ribavirin produces a significantly improved and sustained antiviral response compared with interferon alfa-2b plus ribavirin.¹ Peginterferon alfa-2b has an extended serum half-life that provides constant viral suppression for 7 days, thus allowing once-weekly dosing and an enhanced clinical efficacy.¹ While interferon alfa-2b has been used to treat T-cell lymphoma,^2-3 we report herein the significant efficacy of peginterferon alfa-2b for treatment of skin lesions caused by mycosis fungoides (MF).

A 67-year-old Japanese man was referred to our hospital with a 6-month history of multiple, asymptomatic brown-red colored scaly erythematous macules and plaques over his arms and legs (Figure, A and B). He had not received any medications prior to the onset of his skin eruption. A skin biopsy . . . [Full Text of this Article]

AUTHOR INFORMATION
Teruki Yanagi, MD; Tadamichi Shimizu, MD, PhD; Hideyuki Ujiie, MD; Miki Ito, MD; Riichiro Abe, MD, PhD; Yukiko Tsuji-Abe, MD, PhD; Shuhei Hige, MD, PhD; Hiroshi Shimizu, MD, PhD